Safety study of a new shingles vaccine
Part of Infections clinical trials.
This trial tests a new investigational shingles vaccine to see if it is safe and produces an immune response in healthy adults 40 and older. Participating could help protect against shingles and its complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years old or older and in generally good health.
- You should not have had shingles (zoster) before.
- You should not have received a chickenpox (varicella) or shingles vaccine in the past.
- You must not have serious allergies to vaccine components or a history of severe allergic reactions to vaccines.
- You cannot have certain medical conditions, such as heart problems, nerve disorders, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational vaccine (SYS6017) to see how well it works and if it's safe for adults 40 and older. The vaccine aims to prevent shingles, a painful rash caused by the same virus as chickenpox.
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.